NC410 (Not yet branded)
Other Medications
Description
NC410 is an experimental immunotherapy agent currently in early-phase clinical development for advanced solid tumors, including colorectal cancer. This compound is specifically designed for patients with microsatellite stable (MSS) tumors, which typically respond poorly to conventional immune checkpoint inhibitors. NC410 is being evaluated both as a single agent and in combination with pembrolizumab for patients with advanced unresectable or metastatic solid tumors.
Mechanism of Action
Based on its development for MSS tumors and combination with pembrolizumab, NC410 appears to target pathways that enhance immune system activation in immunologically "cold" tumors. The drug likely works to overcome immune suppression mechanisms that prevent effective T-cell infiltration and activation in MSS colorectal cancers, potentially through modulation of innate immune signaling or tumor microenvironment reprogramming.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.